Literature DB >> 17472539

The management of psychosis in movement disorder patients.

Kelvin L Chou1, Leora L Borek, Joseph H Friedman.   

Abstract

Psychosis may be seen with several movement disorders. As pharmacological treatments can sometimes worsen movement disorders, psychosis in these situations can be complex for clinicians to manage. This review covers the management of psychosis in three different movement disorders: Parkinson's disease, dementia with Lewy bodies and Huntington's disease.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17472539     DOI： 10.1517/14656566.8.7.935

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


  3 in total

1.  Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling.

Authors:  Jean-Francois Poulin; Jian Zou; Janelle Drouin-Ouellet; Kwang-Youn A Kim; Francesca Cicchetti; Rajeshwar B Awatramani
Journal:  Cell Rep       Date:  2014-10-30       Impact factor: 9.423

2.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

3.  The Spectrum of Psychiatric Pathology in a Patient with Genetically Verified Huntington's Disease.

Authors:  Samir Alkabie; Daljinder Singh; Amy Hernandez; Rhaisa Dumenigo
Journal:  Case Rep Psychiatry       Date:  2015-09-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.